Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Small cell lung cancer
What is your experience with the modified ramp-up of tarlatamab, where an extra 5 mg is given in the ramp-up phase before increasing to the full dose?
Related Questions
In a patient with node-positive limited-stage small cell lung cancer, how do you approach radiation in a patient whose small primary tumor resolves after one cycle of chemotherapy?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
Would you consider delaying Tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
How would you approach treatment for patients with limited stage small cell lung cancer (SCLC) who, after induction chemotherapy with carboplatin/etoposide, develop a new contralateral lung nodule confirmed as SCLC, while their primary tumor shows a partial response?
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
Would you change systemic therapy in a patient with SCLC with stable systemic disease but CNS progression?
Can Dupixent and Durvalumab be used at the same time in a patient with extensive stage small cell lung cancer?
How would active Crohn's on Adalimumab affect the adjuvant management of a T2aN0M0 gallbladder cancer?
Are there any trials looking at alternative treatments for patients who otherwise would receive 2 years of ADT but have the HSD3B1 gene (homozygous vs heterozygous)?
What is your preferred way of administering nivolumab/ipilimumab in GI cancers?
